Clinical Trials Logo
  1. Home
  2. Sepsis
  3. NCT06267742
  4. Details
NCT06267742 Clinical Trial

Clinical Trial to Evaluate MDW for Early Detection of Sepsis

Sepsis Clinical Trial

Official title:
Clinical Trial to Evaluate Early Sepsis Indicator Monocyte Distribution Width (MDW) for Early Detection of Sepsis or Developing Sepsis

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT06267742
Other study ID # CHN097
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date June 23, 2022
Est. completion date September 30, 2024

Study information
Verified date February 2024
Source Beckman Coulter, Inc.
Contact DI HOU, Ph.D
Phone +861065213000
Email dhou01@beckman.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This study is intended to clinically verify Monocyte Distribution Width (MDW) parameter of DxH 900 Hematology Analyzer for use in early detection and risk assessment of sepsis, severe sepsis, and septic shock in critically ill patients in Emergency Department (ED). This study is also aimed to provide study supporting data for the product to be marketed in China.

Description:

To verify the clinical performance of MDW parameter in detection of sepsis through a multicenter, prospective study of adults undergoing complete blood count with differential ("CBC with differential") in the ED. To clarify the cutoff 20.0 established in the pivotal trial. The cutoff was established for the objective of achieving the highest sensitivity at the optimal specificity level. Patients whose MDW value is higher than the cutoff will be identified as sepsis patients and those whose MDW value is equal to or lower than the cutoff are non-sepsis patients.

Recruitment information / eligibility
Status Recruiting
Enrollment 2200
Est. completion date September 30, 2024
Est. primary completion date March 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Adult subjects (18-89 years) presenting to ED. - CBC with Differential performed upon presentation as part of standard of care. - Subject scheduled for at least 12 hours follow-up during ED (or inpatient, if admitted to the hospital) visit - Signed the informed consent form Exclusion Criteria: - Subjects previously enrolled in this study (i.e., re-enrollment to this study is not allowed). - The subject is discharged from the hospital within 12 hours after ED visit

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Complete Blood Count (CBC) with Differential
CBC with Differential including Monocyte Distribution Width (MDW)

Locations
Country Name City State
China Peking Union Medical College Hospital Beijing
China West China Hospital, Sichuan University Chengdu
China The Second Affiliated Hospital of Zhejiang University School of Medicine Hangzhou

Sponsors (4)
Lead Sponsor Collaborator
Beckman Coulter, Inc. Peking Union Medical College Hospital, Second Affiliated Hospital, School of Medicine, Zhejiang University, West China Hospital

Country where clinical trial is conducted

China, 

Outcome
Type Measure Description Time frame Safety issue
Primary sensitivity, specificity sensitivity (percentage of patients with sepsis correctly identified), specificity (percentage of non-sepsis patients correctly identified) according to Sepsis-2 2022.3-2024.3
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05095324 - The Biomarker Prediction Model of Septic Risk in Infected Patients
Completed NCT02714595 - Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens Phase 3
Completed NCT03644030 - Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
Completed NCT02867267 - The Efficacy and Safety of Ta1 for Sepsis Phase 3
Completed NCT04804306 - Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
Recruiting NCT05578196 - Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections. N/A
Terminated NCT04117568 - The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
Completed NCT03550794 - Thiamine as a Renal Protective Agent in Septic Shock Phase 2
Completed NCT04332861 - Evaluation of Infection in Obstructing Urolithiasis
Completed NCT04227652 - Control of Fever in Septic Patients N/A
Enrolling by invitation NCT05052203 - Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
Terminated NCT03335124 - The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock Phase 4
Recruiting NCT04005001 - Machine Learning Sepsis Alert Notification Using Clinical Data Phase 2
Completed NCT03258684 - Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock N/A
Recruiting NCT05217836 - Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
Completed NCT05018546 - Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery N/A
Completed NCT03295825 - Heparin Binding Protein in Early Sepsis Diagnosis N/A
Not yet recruiting NCT06045130 - PUFAs in Preterm Infants
Not yet recruiting NCT05361135 - 18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia N/A
Not yet recruiting NCT05443854 - Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01) Phase 3